Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk
- PMID: 27510185
- PMCID: PMC5509538
- DOI: 10.1007/s10549-016-3939-0
Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with chemotherapy, but researchers rarely study its risk factors, fall risk, and prevalence in long-term breast cancer survivors. We aimed to determine CIPN prevalence, risk factors, and association with psychological distress and falls among long-term breast cancer survivors. We conducted Cross-sectional analyses among postmenopausal women with a history of stage I-III breast cancer who received taxane-based chemotherapy. Participants reported neuropathic symptoms of tingling/numbness in hands and/or feet on a 0-10 numerical rating scale. We conducted multivariate logistic regression analyses to evaluate risk factors associated with the presence of CIPN and the relationship between CIPN and anxiety, depression, insomnia, and patient-reported falls. Among 296 participants, 173 (58.4 %) reported CIPN symptoms, 91 (30.7 %) rated their symptoms as mild, and 82 (27.7 %) rated them moderate to severe. Compared with women of normal weight, being obese was associated with increased risk of CIPN (adjusted OR 1.94, 95 % CI: 1.03-3.65). Patients with CIPN reported greater insomnia severity, anxiety, and depression than those without (all p < 0.05). Severity of CIPN was associated with higher rates of falls, with 23.8, 31.9, and 41.5 % in the "no CIPN," "mild," and "moderate-to-severe" groups, respectively, experiencing falls (p = 0.028). The majority of long-term breast cancer survivors who received taxane-based chemotherapy reported CIPN symptoms; obesity was a significant risk factor. Those with CIPN also reported increased psychological distress and falls. Interventions need to target CIPN and comorbid psychological symptoms, and incorporate fall prevention strategies for aging breast cancer survivors.
Keywords: Breast cancer; Chemotherapy; Falls; Obesity; Peripheral neuropathy.
Conflict of interest statement
Figures
Similar articles
-
The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.JAMA Neurol. 2016 Jul 1;73(7):860-6. doi: 10.1001/jamaneurol.2016.0383. JAMA Neurol. 2016. PMID: 27183099 Free PMC article.
-
Fall Risk Associated with Taxanes: Focus on Chemotherapy-Induced Peripheral Neuropathy.Semin Oncol Nurs. 2024 Aug;40(4):151687. doi: 10.1016/j.soncn.2024.151687. Epub 2024 Jul 15. Semin Oncol Nurs. 2024. PMID: 39013733 Clinical Trial.
-
Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.Support Care Cancer. 2021 Jun;29(6):2959-2971. doi: 10.1007/s00520-020-05796-0. Epub 2020 Oct 6. Support Care Cancer. 2021. PMID: 33025227
-
Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review.J Cancer Surviv. 2023 Feb;17(1):222-236. doi: 10.1007/s11764-021-00988-x. Epub 2021 Jan 12. J Cancer Surviv. 2023. PMID: 33438175
-
Chronic chemotherapy-induced peripheral neuropathy: living with neuropathy during and after cancer treatments.Ann Palliat Med. 2025 Mar;14(2):196-216. doi: 10.21037/apm-24-154. Ann Palliat Med. 2025. PMID: 40211744 Review.
Cited by
-
Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy.Acta Oncol. 2024 Aug 5;63:636-641. doi: 10.2340/1651-226X.2024.39895. Acta Oncol. 2024. PMID: 39099324 Free PMC article.
-
Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy.Curr Opin Support Palliat Care. 2024 Mar 1;18(1):30-38. doi: 10.1097/SPC.0000000000000684. Epub 2024 Dec 6. Curr Opin Support Palliat Care. 2024. PMID: 38126251 Review.
-
Mechanistic and thermal characterization of acupuncture for chemotherapy-induced peripheral neuropathy as measured by quantitative sensory testing.Breast Cancer Res Treat. 2023 Feb;197(3):535-545. doi: 10.1007/s10549-022-06846-3. Epub 2022 Dec 17. Breast Cancer Res Treat. 2023. PMID: 36527520 Free PMC article. Clinical Trial.
-
Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.Support Care Cancer. 2019 Jul;27(7):2599-2608. doi: 10.1007/s00520-018-4553-y. Epub 2018 Nov 20. Support Care Cancer. 2019. PMID: 30460399 Free PMC article.
-
Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.Fukushima J Med Sci. 2022 Apr 8;68(1):1-10. doi: 10.5387/fms.2021-32. Epub 2022 Feb 23. Fukushima J Med Sci. 2022. PMID: 35197393 Free PMC article. Review.
References
-
- Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010;6(12):657–66. - PubMed
-
- Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014;40(7):872–82. - PubMed
-
- Seretny M, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155(12):2461–70. - PubMed
-
- Hershman DL, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125(3):767–74. - PubMed
-
- Eckhoff L, et al. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer. 2015;51(3):292–300. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical